Sonelokimab (M1095) + Adalimumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
Apr 25, 2022 → Aug 30, 2023
NCT ID
NCT05322473About Sonelokimab (M1095) + Adalimumab
Sonelokimab (M1095) + Adalimumab is a phase 2 stage product being developed by MoonLake Immunotherapeutics for Hidradenitis Suppurativa. The current trial status is completed. This product is registered under clinical trial identifier NCT05322473. Target conditions include Hidradenitis Suppurativa.
What happened to similar drugs?
1 of 20 similar drugs in Hidradenitis Suppurativa were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05322473 | Phase 2 | Completed |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 39 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 35 |
| Placebo + Adalimumab | AbbVie | Approved | 43 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 47 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Lutikizumab | AbbVie | Phase 2 | 42 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 39 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 27 |
| Anifrolumab | AstraZeneca | Phase 2 | 39 |